1.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EGF110656, EGF110656-TRIO-CIRG 013, NCT00680901
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: TPU S-1301, NCT00400179
|
|
3.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: VU-VICC-GI-0622, VICC-GI-0622, 6980, NCI-6980, NCT00397384
|
|
4.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: H-22706, NCT00390182
|
|
5.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: 2005-0445, NCT00492817
|
|
6.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CTCT 06-11, NCT00493883
|
|
7.
|
Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: ID02-446, NCT00508443
|
|
8.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 2004-0290, NCT00526110
|
|
9.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 82 Sponsor: Other Protocol IDs: Pro00002207, SPS 151596, NCT00578071
|
|
10.
|
Phase: Phase II Type: Treatment Status: Active Age: 16 and over Sponsor: NCI Protocol IDs: NCI-04-C-0273, NCI-6332, DELCATH-G990039, NCT00096083
|
|
11.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: WSU-D-2840, UMCC-2005-052, AVENTIS-WSU-D-2840, NCT00217581
|
|
12.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 05-113, NCT00130689
|
|
13.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 3G-03-5, NCT00183872
|
|
14.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: DOCOX_C_00082, EudraCT # : 2005-005464-92, NCT00382720
|
|
15.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-06095, NCT00397904
|
|
16.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: MSKCC-06096, NCT00403468
|
|
17.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: EPROST-20040005, EPROST-20040005, SCCC-2003150, SCCC-20050983, AVENTIS-SCCC-2003150, SCCC-20040005, NCT00448682
|
|
18.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 8797, NCT00447330
|
|
19.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: NCI Protocol IDs: CINJ-3330, NCT00161187
|
|
20.
|
Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: VU-VICC-GI-0716, VICC GI 0716, NCT00514020
|
|
21.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 06-103, NCT00515411
|
|
22.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 20060439, NCT00583674
|
|
23.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TORI GI-05, BB-IND 77,805, NCT00591123
|
|
24.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: IMGN 102, NCT00620607
|
|
25.
|
Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA182-026, NCT00633789
|